Phase IIa Trial Testing Three Doses of CIT-013 for Adults With Moderately Active Rheumatoid Arthritis

What this Trial Is About

Researchers are evaluating the effects of CIT-013 on adults with moderately active rheumatoid arthritis RA. The study aims to find out if CIT-013 can reduce disease activity and to monitor any medical problems that may occur during treatment. This Phase IIa trial compares CIT-013 at three different dose levels to a placebo to determine its impact on RA symptoms. Participants will receive subcutaneous injections of CIT-013 or placebo every other week over 12 weeks. The treatment involves multiple arms, including low, medium, and high doses of CIT-013, as well as a placebo group. Each participant receives 3 to 6 injections according to their assigned dose group. The study includes a randomized, double-blind design to fairly compare the effects of the different doses and placebo. During the trial, participants will visit the clinic every two weeks for checkups and tests. Researchers will monitor disease activity using the DAS28-CRP score at week 6 compared to baseline. Safety is assessed by tracking treatment-emergent adverse events over 12 weeks and measuring CIT-013 levels in the blood at various time points. Participants will keep track of their symptoms throughout the study, which lasts about three months.

A Study With CIT-013 in RA Patients